BOSTON, MASSACHUSETTS, & PARIS, FRANCE, June 26, 2019 – PathMaker Neurosystems Inc. (“PathMaker”) is very pleased to announce that it has been named as the 2019 recipient of the CCI France International Trophy for Innovation at this year’s Trophées CCI France International. PathMaker Neurosystems, a clinical-stage bioelectronic medicine company developing breakthrough non- invasive systems for the treatment of patients with spasticity and paralysis, is based on the pioneering work of Dr. Zaghloul Ahmed of The City University of New York.
Under the auspices of CCI France International, an international trade and development organization, and the patronage of the President of France, Emmanuel Macron, this prestigious French prize is awarded to recognize a company, across all technology sectors, that has developed a technological innovation which contributes to the development of economic relations between France, French companies, and the rest of the world. Selection criteria include major investments in research and development, use of new technologies, high growth potential, originality, avant-garde projects, and innovative ideas. Now in its second year of a global program, CCI France International selected PathMaker as one of 8 award recipients from amongst 150 nominees from 40 countries and awarded it the Innovation Prize.
“We are incredibly honored to have been named the recipient of this award, and would like to express our sincere appreciation to the CCI France International committee for this kind recognition of PathMaker’s progress in developing MyoRegulator®, our first-in-class, non-invasive device for the treatment of patients suffering from spasticity,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “Building on the momentum we received last year from the French- American Business (FAB) Award for Startup of the Year from FACCNE, the 2019 CCI France International Trophy for Innovation is a testament to the work done by our team and collaborators in bringing this breakthrough device to patients.”
###
About CCI France International
CCI France International is a French non-profit association, which brings together 120 French Chambers in 90 countries, supporting 35,000 members worldwide. CCI France International was founded in 1907 to develop economic relations between France, French companies, and the rest of the world by working closely with French authorities and French institutions worldwide.
About French-American Chamber of Commerce, New England Chapter (FACCNE)
FACCNE is a non-profit, independent, member-driven organization dedicated to building a strong business community between France and New England. Since 1985, the FACCNE has been the primary solution in New England to facilitate interaction between French and American professionals. FACCNE promotes businesses by connecting entrepreneurs, business leaders and seasoned professionals through networking events, industry-specific workshops, and educational seminars and conferences. FACCNE also offers workshops for the development of young professionals.
About PathMaker Neurosystems Inc.
PathMaker Neurosystems is a clinical-stage bioelectronic medicine company developing breakthrough non-invasive systems for the treatment of patients with chronic neuromotor conditions. With offices in Boston (U.S.) and Paris (France), we are collaborating with world-class institutions including the Brain and Spine Institute (Institut du Cerveau et de la Moelle Epinière – ICM) at the Pitié-Salpêtrière Hospital in Paris to rapidly bring to market disruptive products for treating spasticity, paralysis and muscle weakness. The company is based on the pioneering work of Dr. Zaghloul Ahmed, Professor and Chairman, Department of Physical Therapy and Professor, Center for Developmental Neuroscience, CUNY, who is Scientific Founder of PathMaker Neurosystems. The Company’s technology has been exclusively licensed from City University of New York, and now is covered by over 29 issued patents. In January 2019, we announced a collaboration and distribution agreement with WeHealth Digital Medicine commercialize the MyoRegulator® device worldwide, excluding US and Japan territories retained by PathMaker. More than 48 million patients in the U.S., Europe and China suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders. At PathMaker, we are opening up a new era of non-invasive neurotherapy for patients suffering from chronic neuromotor conditions. For more information, please visit the company website at //www.
The City University of New York is the nation’s leading urban public university. Founded in New York City in 1847, the University comprises 24 institutions: 11 senior colleges, seven community colleges, and additional professional schools. The University serves nearly 275,000 degree-credit students and 218,083 adults, continuing and professional education students.
For more information, please visit //www.
Media Contacts:
Sharon Correia, Senior Vice President, Integrated Communications LaVoieHealthScience
scorreia@lavoiehealthscience.com
Lisa DeScenza, Assistant Vice President, Integrated Communications LaVoieHealthScience
ldescenza@lavoiehealthscience.com
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.